top
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
Key takeaways
- Prefer the Guardian on Google GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications.
- The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer.
- The deal includes two late-stage next-generation treatments for non-small cell lung cancer which are being reviewed by the US regulator, the FDA, with decisions expected in September and November.
Why this matters: a developing story that could shape the day's news cycle.
GSK offices in London Photograph: Chris J Ratcliffe/Reuters View image in fullscreen GSK offices in London Photograph: Chris J Ratcliffe/Reuters GSKGSK to buy US cancer treatment firm Nuvalent for $10.6bn British drugmaker’s new chief executive Luke Miels announces one of its biggest deals
Prefer the Guardian on Google GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications.
The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer.
Article preview — originally published by The Guardian. Full story at the source.
Read full story on The Guardian →
More top stories
Also covered by
Financial Times
GSK in talks to buy cancer biotech Nuvalent for more than $9bn
Investing.com
UK’s GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
Investing.com
GSK in talks to buy cancer drugmaker Nuvalent for over $9 bln, FT reports
STAT News
STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
Aggregated and edited by the Scoop newsroom. We surface news from The Guardian alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop